ReviewObesity reviews : an official journal of the International Association for the Study of Obesity2025
Role of epicardial adipose tissue in heart failure with preserved ejection fraction: An emerging molecular mechanism and therapeutic potential.
Review in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Heart's Hidden Influencer: Epicardial Adipose Tissue in the Pathogenesis of Heart Failure.Cardiology discovery · 2026Review
- The 'obesity paradox' in patients undergoing transcatheter aortic valve implantation. A specialized narrative review.American heart journal plus : cardiology research and practice · 2026Review
- Construction of a predictive model for the efficacy of enhanced external counterpulsation therapy in patients with heart failure with preserved ejection fraction based on automated machine learning and echocardiography.Frontiers in cardiovascular medicine · 2026Article
- Epicardial adipose tissue as a metabolically active visceral fat depot: an emerging target in cardiovascular disease.Frontiers in cardiovascular medicine · 2026Review
- Impact of epicardial adipose tissue volume and hypertension on left ventricular hypertrophy in preclinical heart failure patients with metabolic syndrome.BMC cardiovascular disorders · 2025Article
- Beyond Traditional Risk Factors: Integrating Epicardial Adipose Tissue into the Comorbidity Landscape of HFpEF.Journal of clinical medicine · 2025Review
- Do Rats Have Epicardial Adipose Tissue?Biomedicines · 2025Article
- Role of epicardial adipose tissue in heart failure with preserved ejection fraction: An emerging molecular mechanism and therapeutic potential.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- The Hidden Price of Plenty: Oxidative Stress and Calorie-Induced Cardiometabolic Dysfunction.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
With the evolving landscape of diseases, heart failure with preserved ejection fraction (HFpEF) now encompasses more than half of all heart failure patients. This condition is clinically diverse, involving multiple organ systems and often occurring alongside the aging process. To deeply investigate the common pathogenesis of HFpEF and to explore new therapeutic approaches is of great significance for the treatment of HFpEF. Epicardial adipose tissue (EAT) is not only a dynamic organ with biological functions but also physically adjacent to the myocardium and coronary arteries, endowing it with unique properties as a visceral fat depot. During pathology, EAT can secrete adipocytokines via paracrine mechanisms, establishing direct communication with the heart and vascular, thereby impacting cardiac function. This review aims to elucidate the intricate relationship between EAT and cardiac function in HFpEF, delineate the roles of adipocytes, macrophages, lymphocytes, and stem cells within EAT in HFpEF, and summarize the progress in research regarding drug therapies targeting EAT for HFpEF treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.